{"id":754824,"date":"2023-05-04T08:50:16","date_gmt":"2023-05-04T12:50:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/"},"modified":"2023-05-04T08:50:16","modified_gmt":"2023-05-04T12:50:16","slug":"hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/","title":{"rendered":"HOOKIPA Pharma to Report First Quarter 2023 Financial Results\u00a0and Recent Business Highlights on May 11, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK and VIENNA, Austria, May  04, 2023  (GLOBE NEWSWIRE) &#8212; HOOKIPA Pharma Inc. (NASDAQ: HOOK, \u2018HOOKIPA\u2019), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its first quarter 2023 financial results and business highlights on May 11, 2023.<\/p>\n<p align=\"justify\">The company will not be conducting a conference call in conjunction with this financial release.<\/p>\n<p align=\"justify\">\n        <strong>About HOOKIPA<\/strong><br \/>\n        <br \/>HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA\u2019s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA\u2019s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed programs. HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.<\/p>\n<p align=\"justify\">Find out more about HOOKIPA online at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vVpKYN746viKkObFgaDx0fdAHnEJYjgwlnmrtkE8nscymcwcAyIWcZNANxlhOuoaZ0WfoVLVzyM4XiJiJjLU1GHKaoVn2znn9HW16balMss=\" rel=\"nofollow noopener\" target=\"_blank\">www.hookipapharma.com<\/a>.<\/p>\n<p>\n        <strong>Forward Looking Statements<br \/><\/strong>Certain statements set forth in this press release constitute \u201cforward-looking\u201d statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as \u201cbelieves,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cpotential,\u201d \u201cwould\u201d or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA\u2019s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA\u2019s programs\u2019 early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA\u2019s ability to successfully establish, protect and defend its intellectual property,<strong>\u00a0<\/strong>risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises, the impact of COVID-19 on the enrollment of patients and timing of clinical results, and other matters that could affect the sufficiency of existing cash to fund\u00a0operations. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA\u2019s annual report on Form 10-K for the year ended December 31,\u00a02022, which is available on the Security and Exchange Commission\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VA7YymwgTkB5mcD1ETI0O9hDeJS2_TiYmVTYm7b0VE89Do1qN0p0-QQ9FJc3SnuxfEnWe1YnOIdmAIuBNtXDOw==\" rel=\"nofollow noopener\" target=\"_blank\">www.sec.gov<\/a> and HOOKIPA\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vVpKYN746viKkObFgaDx0fdAHnEJYjgwlnmrtkE8nse5F2-C_zkFfS4aeMzdDZJ1iXy7euXZWKvMk2yqbCr9R9Y_vIqXZNqybqlIfpFDbBE=\" rel=\"nofollow noopener\" target=\"_blank\">www.hookipapharma.com<\/a>.<\/p>\n<p align=\"justify\">Investors and others should note that we announce material financial information to our investors using our investor relations website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d6hTg78T-01F_j54evs5zFFdA5LlZSKOkCYSUXf_XBDTPwZbX2wusWaqk9gC47ki1eHQ8kaJ5ZwL1eyjfFdjwLtk7gYf8UUmXzah_m7puK3ZBcUJY5q1ybkKAFq25G4Q7IFWGnrr_6_gxt77bg8laNvQmwmToSgDHRzwzJ7ZShUK28q8-lSVsjfFw88iKe8VcrAM0dINnpe9WyFVvzFU98R-XBLf-NlxAgTEcAQcPtgaaMO6YNYzA6fnmUfl_Wjtp1UFTvnpxi0_Wqt_kqKF-BChrBWnQJSJpNK9RrZ5kF8=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.hookipapharma.com\/<\/a>), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.<\/p>\n<p>For further information, please contact:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\n            <strong>Media<\/strong>\n          <\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\n            <strong>Investors<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>Instinctif Partners<\/td>\n<td>Reinhard Kandera<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>Chief Financial Officer<\/td>\n<\/tr>\n<tr>\n<td>\n            <a href=\"mailto:hookipa@instinctif.com\" rel=\"nofollow noopener\" target=\"_blank\">hookipa@instinctif.com<\/a>\n          <\/td>\n<td>\n            <a href=\"mailto:IR@hookipapharma.com\" rel=\"nofollow noopener\" target=\"_blank\">IR@hookipapharma.com<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td>+44 (0) 7457 2020<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTkxNyM1NTc1MDI1IzIxNTY5MjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZGE3Y2EyOTQtODAzYy00NTFjLWEwNmQtMGEyMjE2MjIyOTJkLTExNjg0OTM=\/tiny\/HOOKIPA-Pharma-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) &#8212; HOOKIPA Pharma Inc. (NASDAQ: HOOK, \u2018HOOKIPA\u2019), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its first quarter 2023 financial results and business highlights on May 11, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA\u2019s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;HOOKIPA Pharma to Report First Quarter 2023 Financial Results\u00a0and Recent Business Highlights on May 11, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754824","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HOOKIPA Pharma to Report First Quarter 2023 Financial Results\u00a0and Recent Business Highlights on May 11, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HOOKIPA Pharma to Report First Quarter 2023 Financial Results\u00a0and Recent Business Highlights on May 11, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) &#8212; HOOKIPA Pharma Inc. (NASDAQ: HOOK, \u2018HOOKIPA\u2019), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its first quarter 2023 financial results and business highlights on May 11, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA\u2019s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T &hellip; Continue reading &quot;HOOKIPA Pharma to Report First Quarter 2023 Financial Results\u00a0and Recent Business Highlights on May 11, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T12:50:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTkxNyM1NTc1MDI1IzIxNTY5MjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HOOKIPA Pharma to Report First Quarter 2023 Financial Results\u00a0and Recent Business Highlights on May 11, 2023\",\"datePublished\":\"2023-05-04T12:50:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\\\/\"},\"wordCount\":594,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTkxNyM1NTc1MDI1IzIxNTY5MjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\\\/\",\"name\":\"HOOKIPA Pharma to Report First Quarter 2023 Financial Results\u00a0and Recent Business Highlights on May 11, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTkxNyM1NTc1MDI1IzIxNTY5MjI=\",\"datePublished\":\"2023-05-04T12:50:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTkxNyM1NTc1MDI1IzIxNTY5MjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTkxNyM1NTc1MDI1IzIxNTY5MjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HOOKIPA Pharma to Report First Quarter 2023 Financial Results\u00a0and Recent Business Highlights on May 11, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HOOKIPA Pharma to Report First Quarter 2023 Financial Results\u00a0and Recent Business Highlights on May 11, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/","og_locale":"en_US","og_type":"article","og_title":"HOOKIPA Pharma to Report First Quarter 2023 Financial Results\u00a0and Recent Business Highlights on May 11, 2023 - Market Newsdesk","og_description":"NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) &#8212; HOOKIPA Pharma Inc. (NASDAQ: HOOK, \u2018HOOKIPA\u2019), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its first quarter 2023 financial results and business highlights on May 11, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA\u2019s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T &hellip; Continue reading \"HOOKIPA Pharma to Report First Quarter 2023 Financial Results\u00a0and Recent Business Highlights on May 11, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-04T12:50:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTkxNyM1NTc1MDI1IzIxNTY5MjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HOOKIPA Pharma to Report First Quarter 2023 Financial Results\u00a0and Recent Business Highlights on May 11, 2023","datePublished":"2023-05-04T12:50:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/"},"wordCount":594,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTkxNyM1NTc1MDI1IzIxNTY5MjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/","name":"HOOKIPA Pharma to Report First Quarter 2023 Financial Results\u00a0and Recent Business Highlights on May 11, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTkxNyM1NTc1MDI1IzIxNTY5MjI=","datePublished":"2023-05-04T12:50:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTkxNyM1NTc1MDI1IzIxNTY5MjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTkxNyM1NTc1MDI1IzIxNTY5MjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hookipa-pharma-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-11-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HOOKIPA Pharma to Report First Quarter 2023 Financial Results\u00a0and Recent Business Highlights on May 11, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754824"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754824\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}